MA7 Ventures
Almaty, Kazakhstan
Overview
MA7 Ventures is a venture capital firm that provides funding and support to tech startups and visionary founders, focusing on fostering innovation and growth within the startup ecosystem. The firm engages in identifying high-potential companies and offers strategic guidance, mentorship, and resources to help them scale effectively. MA7 Ventures specializes in various sectors, including software, fintech, and digital services, aiming to create long-term value for its portfolio companies while contributing to the overall development of the technology landscape. Through its investment approach, MA7 Ventures facilitates connections between startups and industry experts, enhancing opportunities for collaboration and market expansion.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Venture Capital
Investment portfolio
- Liki24
Participated · Series A · Jul 2025
Founded in 2017, Liki24 connects consumers with thousands of pharmacies, letting users choose one-hour local delivery, next-day domestic delivery, or lower-cost cross-border shipping for medicines, supplements, OTC drugs, and medical cosmetics. The platform relies heavily on AI for product matching, routing split-leg logistics, multilingual customer support, and personalized recommendations. Liki24 now operates in Ukraine, 10 additional EU countries, and the UK, with 70 % of its revenue coming from the EU while Ukrainian revenue has still doubled since the 2022 invasion. Key operating improvements include a sevenfold reduction in cross-border delivery times and a fivefold cut in costs, while support headcount dropped from 80 to about 40 thanks to AI. The company is extending its ecosystem with a lab-test marketplace and a preventive health coaching service that will integrate diagnostics, coaching, doctor access, and product delivery. To date it has raised €19 million in equity financing to fund this expansion. Management positions the €400 billion fragmented European pharmacy market as its primary growth opportunity.
Team
No current team members are available.